| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,653,000 |
| Market
Cap: |
2.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.187 - $0.187 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiora Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mann Brenda |
VP of Research & Development |
• – – |
2021-03-03 |
4 |
D |
$5.46 |
$1,048 |
D/D |
(192) |
16,076 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2021-03-03 |
4 |
D |
$5.46 |
$1,190 |
D/D |
(218) |
24,113 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2021-03-03 |
4 |
D |
$5.46 |
$1,048 |
D/D |
(192) |
16,110 |
|
- |
|
| From Stephen |
Executive Chairman |
• • – |
2021-02-02 |
4 |
D |
$6.34 |
$22,456 |
D/D |
(3,542) |
73,746 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2021-02-02 |
4 |
D |
$6.34 |
$6,277 |
D/D |
(990) |
16,302 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2021-02-02 |
4 |
D |
$6.34 |
$6,264 |
D/D |
(988) |
16,268 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2021-02-02 |
4 |
D |
$6.34 |
$8,128 |
D/D |
(1,282) |
24,331 |
|
- |
|
| Obermayr Franz |
Acting CEOOfficer |
• – – |
2021-02-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
101,613 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2021-01-06 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
3,346,601 |
2.17 |
- |
|
| Boyd Steven |
Director |
– • • |
2021-01-06 |
4 |
B |
$5.23 |
$8,000,003 |
D/D |
1,531,101 |
3,346,601 |
3.92 |
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2021-01-04 |
4 |
D |
$4.85 |
$558 |
D/D |
(115) |
25,613 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2021-01-04 |
4 |
D |
$4.85 |
$558 |
D/D |
(115) |
17,256 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2021-01-04 |
4 |
D |
$4.85 |
$558 |
D/D |
(115) |
17,292 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2021-01-04 |
4 |
D |
$4.85 |
$3,419 |
D/D |
(705) |
77,288 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2020-12-07 |
4 |
D |
$3.76 |
$342 |
D/D |
(91) |
25,728 |
|
- |
|
| From Stephen |
President and CEO |
• – – |
2020-12-07 |
4 |
D |
$3.76 |
$2,211 |
D/D |
(588) |
77,993 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2020-12-07 |
4 |
D |
$3.76 |
$342 |
D/D |
(91) |
17,407 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2020-12-07 |
4 |
D |
$3.76 |
$342 |
D/D |
(91) |
17,371 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2020-11-02 |
4 |
D |
$3.51 |
$337 |
D/D |
(96) |
17,462 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2020-11-02 |
4 |
D |
$3.51 |
$340 |
D/D |
(97) |
25,819 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2020-11-02 |
4 |
D |
$3.51 |
$340 |
D/D |
(97) |
17,498 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2020-11-02 |
4 |
D |
$3.51 |
$2,187 |
D/D |
(623) |
78,581 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2020-10-02 |
4 |
D |
$3.88 |
$380 |
D/D |
(98) |
17,558 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2020-10-02 |
4 |
D |
$3.88 |
$380 |
D/D |
(98) |
17,595 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2020-10-02 |
4 |
D |
$3.88 |
$2,448 |
D/D |
(631) |
79,204 |
|
- |
|
289 Records found
|
|
Page 3 of 12 |
|
|
